Page 2192 - Hematology_ Basic Principles and Practice ( PDFDrive )

1943.e2 Part XII Hemostasis and Thrombosis

inhibition with gradual recovery from GP IIb/IIIa receptor blockade. 77. George JN, Shattil SJ: The clinical importance of acquired abnormali-
Circulation 97:1680, 1998. ties of platelet function. N Engl J Med 324:27, 1991.
52. Douketis JD, Berger PB, Dunn AS, et al: The perioperative manage- 78. McQueen EG, Facoory B, Faed JM: Non-steroidal anti-inflammatory
ment of antithrombotic therapy: American College of Chest Physi- drugs and platelet function. N Z Med J 99:358, 1986.
cians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 79. Favaloro EJ: Clinical application of the PFA-100. Curr Opin Hematol
133:299S, 2008. 9:407, 2002.
53. Kohl DW, Slavik KJ, Kamath G, et al: High-dose abciximab during 80. Thomas P, Hepburn B, Kim HC, et al: Nonsteroidal anti-inflammatory
coronary angioplasty in a patient with essential thrombocytosis. J drugs in the treatment of hemophilic arthropathy. Am J Hematol
Invasive Cardiol 10:173, 1998. 12:131, 1982.
54. Scarborough RM, Rose JW, Hsu MA, et al: Barbourin. A GPIIb-IIIa- 81. Blann AD, Nadar S, Lip GY: Pharmacological modulation of platelet
specific integrin antagonist from the venom of Sistrurus m. barbouri. J function in hypertension. Hypertension 42:1, 2003.
Biol Chem 266:9359, 1991. 82. Torfgard KE, Ahlner J: Mechanisms of action of nitrates. Cardiovasc
55. Scarborough RM: Development of eptifibatide. Am Heart J 138:1093, Drugs Ther 8:701, 1994.
1999. 83. Petrikova M, Jancinova V, Nosal R, et al: Antiplatelet activity of
56. King S, Short M, Harmon C: Glycoprotein IIb/IIIa inhibitors: the carvedilol in comparison to propranolol. Platelets 13:479, 2002.
resurgence of tirofiban. Vascul Pharmacol 78:10, 2016. 84. Dash D, Rao K: Effect of propranolol on platelet signal transduction.
57. Tcheng JE, Kereiakes DJ, Lincoff AM, et al: Abciximab readminis- Biochem J 309:99, 1995.
tration: results of the ReoPro Readministration Registry. Circulation 85. Falciani M, Rinaldi B, D’Agostino B, et al: Effects of nebivolol on
104:870, 2001. human platelet aggregation. J Cardiovasc Pharmacol 38:922, 2001.
58. Aster RH: Immune thrombocytopenia caused by glycoprotein IIb/IIIa 86. Lawson D, Mehta J, Mehta P, et al: Cumulative effects of quinidine
inhibitors. Chest 127:53S, 2005. and aspirin on bleeding time and platelet a 2-adrenoceptors: potential
59. Dasgupta H, Blankenship JC, Wood GC, et al: Thrombocytopenia mechanism of bleeding diathesis in patients receiving this combination.
complicating treatment with intravenous glycoprotein IIb/IIIa receptor J Lab Clin Med 108:581, 1986.
inhibitors: a pooled analysis. Am Heart J 140:206, 2000. 87. Sato Y, Fujii S, Imagawa S, et al: Platelet aggregability in patients with
60. Boersma E, Harrington RA, Moliterno DJ, et al: Platelet glycoprotein hypertension treated with angiotensin II type 1 receptor blockers. J
IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all Atheroscler Thromb 14:31, 2007.
major randomised clinical trials. Lancet 359:189, 2002. 88. Serebruany VL, Pokov AN, Malinin AI, et al: Valsartan inhibits platelet
61. Gresele P, Momi S, Falcinelli E: Anti-platelet therapy: phosphodiesterase activity at different doses in mild to moderate hypertensives: Valsartan
inhibitors. Br J Clin Pharmacol 72:634, 2011. Inhibits Platelets (VIP) trial. Am Heart J 151:92, 2006.
62. Cavalcante JW, Santos PR, Jr, Menezes MG, et al: Influence of caffeine 89. Brown CH, III, Natelson EA, Bradshaw W, et al: The hemostatic defect
on blood pressure and platelet aggregation. Arq Bras Cardiol 75:97, produced by carbenicillin. N Engl J Med 291:265, 1974.
2000. 90. Sattler FR, Weitekamp MR, Ballard JO: Potential for bleeding with the
63. Thiele J, Kvasnicka HM, Schmitt-Graeff A: Effects of anagrelide on new b-lactam antibiotics. Ann Intern Med 105:924, 1986.
megakaryopoiesis and platelet production. Semin Thromb Hemost 91. Wisloff F, Godal HC: Prolonged bleeding time with adequate platelet
32:352, 2006. count in hospital patients. Scand J Haematol 27:45, 1981.
64. Andersson BS: Essential thrombocythemia: diagnosis and treatment, 92. Rau J, Simon M, Sander M, et al: Severe bleeding as a result of platelet
with special emphasis on the use of anagrelide. Hematology 7:173, 2002. inhibition caused by floxacillin treatment for endocarditis. J Thorac
65. Kambayashi J, Liu Y, Sun B, et al: Cilostazol as a unique antithrombotic Cardiovasc Surg 146:e63–e65, 2013.
agent. Curr Pharm Des 9:2289, 2003. 93. Shattil SJ, Bennett JS, McDonough M, et al: Carbenicillin and penicil-
66. Aktas B, Utz A, Hoenig-Liedl P, et al: Dipyridamole enhances NO/ lin G inhibit platelet function in vitro by impairing the interaction of
cGMP-mediated vasodilator-stimulated phosphoprotein phosphoryla- agonists with the platelet surface. J Clin Invest 65:329, 1980.
tion and signaling in human platelets: in vitro and in vivo/ex vivo 94. Schulz C, von Beckerath O, Okrojek R, et al: Platelet dysfunction
studies. Stroke 34:764, 2003. and inhibition of multiple electrode platelet aggregometry caused by
67. Marnett LJ, Siedlik PH, Ochs RC, et al: Mechanism of the stimula- penicillin. Thromb J 8:13, 2010.
tion of prostaglandin H synthase and prostacyclin synthase by the 95. Haburchak DR, Head DR, Everett ED: Postoperative hemorrhage
antithrombotic and antimetastatic agent, nafazatrom. Mol Pharmacol associated with carbenicillin administration. Report of two cases and
26:328, 1984. review of the literature. Am J Surg 134:630, 1977.
68. Leonardi-Bee J, Bath PM, Bousser MG, et al: Dipyridamole for 96. Brown RB, Klar J, Lemeshow S, et al: Enhanced bleeding with cefoxitin
preventing recurrent ischemic stroke and other vascular events: a meta- or moxalactam. Statistical analysis within a defined population of 1493
analysis of individual patient data from randomized controlled trials. patients. Arch Intern Med 146:2159, 1986.
Stroke 36:162, 2005. 97. Mihara S, Kakushi H, Shike T, et al: Effects of latamoxef on in vitro
69. Hallas J, Dall M, Andries A, et al: Use of single and combined anti- and ex vivo thromboxane A2 generation in human platelets. Thromb
thrombotic therapy and risk of serious upper gastrointestinal bleeding: Res 49:215, 1988.
population based case-control study. BMJ 333:726, 2006. 98. Lipsky JJ: Antibiotic-associated hypoprothrombinaemia. J Antimicrob
70. Rosen RC, Kostis JB: Overview of phosphodiesterase 5 inhibition in Chemother 21:281, 1988.
erectile dysfunction. Am J Cardiol 92:9M, 2003. 99. Rossi EC, Levin NW: Inhibition of primary ADP-induced platelet
71. Bott SR, Shergill I, Arya M: Epistaxis after sildenafil. J R Soc Med aggregation in normal subjects after administration of nitrofurantoin
95:528, 2002. (furadantin). J Clin Invest 52:2457, 1973.
72. Hicklin LA, Ryan C, Wong DK, et al: Nose-bleeds after sildenafil 100. Ishikawa S, Manabe S, Wada O: Miconazole inhibition of platelet
(Viagra). J R Soc Med 95:402, 2002. aggregation by inhibiting cyclooxygenase. Biochem Pharmacol 35:1787,
73. Sheikh RA, Yasmeen S, Prindiville TP: Hemorrhoidal bleeding associ- 1986.
ated with sildenafil. Am J Gastroenterol 96:2518, 2001. 101. Miki A, Ohtani H, Sawada Y: Warfarin and miconazole oral gel interac-
74. Buxton N, Flannery T, Wild D, et al: Sildenafil (Viagra)-induced tions: analysis and therapy recommendations based on clinical data and
spontaneous intracerebral haemorrhage. Br J Neurosurg 15:347, a pharmacokinetic model. J Clin Pharm Ther 36:642, 2011.
2001. 102. Pastakia KB, Brownson NE, Terle DA, et al: Amphotericin B induced
75. Tzathas C, Christidou A, Ladas SD: Sildenafil (viagra) is a risk factor abnormalities in human platelets. Clin Mol Pathol 49:M301–M307,
for acute variceal bleeding. Am J Gastroenterol 97:1856, 2002. 1996.
76. Gomberg-Maitland M, Olschewski H: Prostacyclin therapies for the 103. Hussein MA, Fletcher R, Long TJ, et al: Transfusing platelets 2 h after
treatment of pulmonary arterial hypertension. Eur Respir J 31:891, the completion of amphotericin-B decreases its detrimental effect on
2008. transfused platelet recovery and survival. Transfus Med 8:43, 1998.